Platform for Aptamer-Mediated Cellular Regulation using Circular RNA Nanodevices

Principal Investigator: 

Samie R. Jaffrey, Professor of Pharmacology

Background & Unmet Need

  • RNA aptamers are small RNAs capable of folding into complex structures, allowing them to bind to metabolites, proteins, or other molecules and thereby regulate cellular functions
  • Various aptamers have been successfully selected against different targets and show promise as a diagnostic, prognostic and therapeutic
  • Efficient RNA circularization has led to the development of aptamers resistant to exonucleases, making them highly stable and abundant within cells
  • However, their constitutive binding can lead to toxicity
  • Allosteric control by theophylline and tetracycline binding aptamers is possible but leads to unwanted biological effects, such as increased cyclic AMP and altered microbiomes and antibiotic resistance
  • Unmet Need: Reliable method to control the activity of RNA aptamers in a reversible and tunable manner with minimal off-target effects

Technology Overview

  • The Technology: A platform for generating acyclovir-controlled RNA nanodevices that can be used for controlling cell physiology
  • The nanodevice incorporates two aptamers: the first aptamer (input) exhibits a conformational change upon binding acyclovir, which stabilizes the second aptamer (output) in a folded conformation that binds to an effector or performs an effector function
  • PoC Data: Engineered an RNA nanodevice that successfully demonstrated acyclovir-dependent control of Broccoli, a fluorogenic aptamer
  • Engineered an RNA nanodevice containing an iron response element (IRE), an aptamer that binds to the major undruggable iron-regulatory proteins (IRPs), enabling tunable repression of free iron levels and thus the inhibition of ferroptosis
  • Compared to samples without acyclovir, those with acyclovir exhibited up to a 126% increase in FTH levels and up to a 22% decrease in TfR expression

Technology Applications

  • A platform for developing RNA-based therapeutics, particularly for controlling iron homeostasis and preventing ferroptosis
  • Integrated into existing gene therapy platforms to enhance the control of gene expression
  • As a tool in for studying cellular processes and pathway regulations

Technology Advantages

  • Reversible and tunable control of aptamer function through external activators, allows for precise modulation and reset of expression
  • Activation by specific, non-toxic small molecules like acyclovir ensures targeted action with minimal side effects
  • Applicable to various cellular functions including mRNA cleavage, splicing, and polyadenylation

Design of RNA nanodevice that enables acyclovirregulated fluorescence.

Intellectual Property

Patents

  • Provisional Application Filed

Cornell Reference

  • 11080

Contact Information

Jamie Brisbois, Ph.D.

For additional information please contact

Jamie Brisbois
Manager, Business Development and Licensing
Phone: (646) 962-7049
Email: jamie.brisbois@cornell.edu